News
Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Feb 27, 2017BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today the appointments of June S. Almenoff, M.D.,...
- Feb 21, 2017
Signs agreement with CCRM for regulatory support of ALS treatment TORONTO, HACKENSACK, N.J. and PETACH TIKVAH, Israel, Feb. 21, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:...
- Feb 16, 2017
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it plans to contract with City of Hope's...
- Feb 6, 2017
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chaim Lebovits, Chief Executive Officer,...
- Jan 30, 2017
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced that it has validated its cryopreservation process...
- Jan 17, 2017
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chaim Lebovits, Chief Executive Officer,...
- Jan 5, 2017
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chaim Lebovits, Chief Executive Officer,...
- Dec 19, 2016Conference Call @ 8:30am Eastern Time Today to Provide Corporate Update and Discuss Plans for 2017
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today provided a corporate update and announced its clinical...
- Dec 15, 2016Legislation Potentially Has Direct and Positive Implications for NurOwn®
BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced its support for the 21st Century Cures Act. The Act,...
- Dec 14, 2016
BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced that new data from the Company's Phase 2 study of NurOwn®...
- Dec 6, 2016Company Explores Regulatory Commercial Pathways for NurOwn®
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that it will hold a conference call on...
- Dec 5, 2016Clinical Data to be Presented by James D. Berry, MD, MPH, and Anthony J. Windebank, MD, Principal Investigators in NurOwn® Phase 2 Trial
BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today data from the Company's Phase 2 study of NurOwn® in...
- Nov 15, 2016
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results and provided a business...
-
Oct 31, 2016
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced that it has been granted United States Patent No....
-
Sep 6, 2016
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chaim Lebovits, Chief Executive Officer,...
- Aug 11, 2016
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results and provided a business...
- Jul 18, 2016NurOwn® was Demonstrated to be Safe and Well Tolerated
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced results from the recently completed U.S....
- Jul 14, 2016Conference Call and Live Webcast at 10am Eastern Time
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will announce results from the recently completed Phase 2...
- May 17, 2016
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that Chaim Lebovits, Chief Executive Officer,...
- May 12, 2016
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that its wholly-owned subsidiary, Brainstorm...
- May 10, 2016
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results and provided a business...
- Mar 29, 2016
Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that Dr. Yael Gothelf, VP Scientific &...
- Mar 10, 2016
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results for the three months and...
- Mar 8, 2016
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that Chaim Lebovits, Chief Executive Officer,...
- Jan 11, 2016Clinical Data Suggest that NurOwn Can Slow Disease Progression in ALS
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced the publication of a paper in the January 2016...
- Jan 11, 2016
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has entered into a collaborative...
- Dec 10, 2015
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has rescheduled its conference call,...
- Dec 7, 2015
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has appointed Dr. Revital...
- Dec 2, 2015
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it will hold a conference call on...
- Dec 1, 2015
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, and Octane Biotech Inc., a Canadian company that focuses on...
- Nov 30, 2015New Grant is the Second Awarded by OCS to Brainstorm in 2015
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that its wholly-owned subsidiary, Brainstorm...
- Nov 17, 2015
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results and provided a business...
- Nov 9, 2015
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the Data and Safety Monitoring Board...
- Oct 16, 2015
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that the Company has been granted a patent by...
- Oct 8, 2015
BrainStorm Cell Therapeutics Inc (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announces that its Chief Scientific Advisor, Prof Daniel Offen,...
- Oct 7, 2015
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the final patient has been treated in its...
- Oct 1, 2015
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will be presenting at the annual Partnering Forum, part of the...
- Sep 22, 2015
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has appointed Mr. Chaim Lebovits, who...
- Sep 2, 2015BrainStorm Cell Therapeutics to Present at Rodman & Renshaw 17th Annual Global Investment Conference
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chief Executive Officer Tony Fiorino, MD,...
- Aug 13, 2015
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results and provided a business...
- Aug 11, 2015
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has completed enrollment in its...
- Aug 6, 2015
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it will report second quarter 2015...
- Aug 3, 2015
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has appointed Yoram Bibring as Chief...
- Jul 6, 2015
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chief Executive Officer Tony Fiorino, MD,...
- Jun 29, 2015
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that has been added to the Russell Microcap®...
- Jun 16, 2015
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, is participating in the Israel Pavilion at the invitation of...
- May 14, 2015
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results and provided a business...
- May 11, 2015
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Dr. Yael Gothelf, Vice President,...
- May 7, 2015
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it will report first quarter 2015...
- Apr 21, 2015Phase 2a Results and New Analyses Presented at American Academy of Neurology
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, is presenting results from its phase 2a study of NurOwn® in...
- Apr 14, 2015
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that results from its phase 2a study of...
- Mar 26, 2015Conference call today at 8.30 a.m. EDT
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results for the three months and...
- Mar 19, 2015
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it will report fourth quarter and full...
- Mar 18, 2015BrainStorm Cell Therapeutics to Present at 3rd Annual Regen Med Investor Day on March 25 in New York
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that CEO Tony Fiorino, MD, PhD, will present at...
- Feb 9, 2015
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has received a Notice of Allowance...
- Feb 4, 2015
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that Chief Executive Officer Tony Fiorino, MD,...
- Feb 3, 2015No Concerns Identified; DSMB Recommends Trial Continues as Planned
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that the Data and Safety Monitoring Board...
- Jan 26, 2015
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced positive results from preclinical studies of...
- Jan 8, 2015Warrant Holders Exercising at a Premium; to Receive New Warrants
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced it has entered into a Warrant Exercise...
- Jan 7, 2015
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that since January 2, 2015 it has received...
- Jan 6, 2015
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that Tony Fiorino, MD, PhD, Chief Executive...
- Jan 5, 2015
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced positive final results from its phase 2a...
- Dec 22, 2014Safety and efficacy findings from interim analysis to be extended with additional data and analyses
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will release the final results from its phase 2a clinical...
- Dec 15, 2014
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that wholly-owned subsidiary Brainstorm Cell...
- Nov 13, 2014Conference call today at 8.30 AM EST
BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results for the three and nine months ending...
-
Nov 5, 2014BrainStorm Cell Therapeutics to Report Third Quarter 2014 Financial Results on Thursday, November 13
BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it will report third quarter 2014 financial...
- Oct 7, 2014
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the United States Food and Drug...
-
Oct 6, 2014
BrainStorm Cell Therapeutics (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that the last patient has completed the last visit...
